دورية أكاديمية

IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion

التفاصيل البيبلوغرافية
العنوان: IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion
المؤلفون: Leilei Zhao, Yudi Wang, Peizheng Mu, Xuehua Zhang, Ruomei Qi, Yurui Zhang, He Zhang, Xiao Zhu, Zhouyan Dong, Yucui Dong
المصدر: Cancer Cell International, Vol 24, Iss 1, Pp 1-15 (2024)
بيانات النشر: BMC, 2024.
سنة النشر: 2024
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LCC:Cytology
مصطلحات موضوعية: Glioblastoma, IGFBP3, PD-L1, JAK2, STAT3, Target therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671
الوصف: Abstract Background Glioblastoma (GBM) characterized by immune escape is the most malignant primary brain tumors, which has strong immunosuppressive effect. Programmed death ligand-1 (PD-L1) is a recognized immunosuppressive member on the surface of tumor cells, and plays a crucial role in immune evasion of tumors. Actually, little is known about the regulation of PD-L1 expression in GBM. Insulin-like growth factor binding protein 3 (IGFBP3) is upregulated in GBM and is related to poor patient prognosis. However, it remains unclear whether IGFBP3 plays a role in the regulation of PD-L1 expression in GBM. Methods The role of IGFBP3 in the glioma immune microenvironment was investigated using the CIBERSORT algorithm. The correlation between IGFBP3 and PD-L1 expression was analyzed using TCGA and CGGA databases. QRT-PCR, immunoblotting and RNA-seq were used to examine the regulatory effect of IGFBP3 on PD-L1 expression. Co-culture assay, cell counting kit (CCK-8), qRT-PCR, ELISA and flow cytometry were performed to explore the function of IGFBP3 in inducing immunosuppression. The biological role of IGFBP3 was verified using immunohistochemical, immunofluorescence and mice orthotopic tumor model. Results In this study, we analyzed immune cells infiltration in gliomas and found that IGFBP3 may be associated with an immunosuppressive microenvironment. Then, by analyzing TCGA and CGGA databases, our results showed that IGFBP3 and PD-L1 expression were positively correlated in GBM patients, but not in LGG patients. In vitro experiments conducted on different GBM cell lines revealed that the overexpression of IGFBP3 led to an increase in PD-L1 expression, which was reversible upon knockdown IGFBP3. Mechanistically, IGFBP3 activated the JAK2/STAT3 signaling pathway, leading to an increase in PD-L1 expression. Additionally, co-culture experiments results showed IGFBP3 overexpression induced upregulation of PD-L1 expression promoted apoptosis in Jurkat cells, and this effect was blocked by IGFBP3 antibody and PDL-1 inhibitors. Importantly, in vivo experiments targeting IGFBP3 suppressed tumor growth and significantly prolonged the survival of mice. Conclusions This research demonstrated IGFBP3 is a novel regulator for PD-L1 expression in GBM, and identified a new mechanism by which IGFBP3 regulates immune evasion through PD-L1, suggesting that IGFBP3 may be a potential novel target for GBM therapy.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1475-2867
Relation: https://doaj.org/toc/1475-2867
DOI: 10.1186/s12935-024-03234-3
URL الوصول: https://doaj.org/article/e8215e18596d4b6fb9f42ae174755243
رقم الأكسشن: edsdoj.8215e18596d4b6fb9f42ae174755243
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14752867
DOI:10.1186/s12935-024-03234-3